The objective of this study was to develop an optimal iron oxide enhanced lymph node MRI protocol and robust image analysis using pre-and-post ferumoxytol T2 and T2* scans in canine patients with HNC. Since those pet patients are naturally prone to HNC, they can serve as a great translational platform for development of novel non-invasive imaging modalities for LN staging and metastasis and to guide anti-lymphangiogenic therapies. The results indicate that Ferumoxytol can be used as T2 negative contrast agent for non-invasive LN staging 48 hrs post-injection. SI normalization should be performed to a phantom or to the brain.
This abstract and the presentation materials are available to members only; a login is required.